Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

NCT01584557 is registered in ClinicalTrials.gov with Cardiovascular Clinical Sciences Inc as lead sponsor.

NCT NCT01584557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01584557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
Lead sponsor
Cardiovascular Clinical Sciences Inc
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
August 31, 2016
Enrollment
250 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure